1038916-11-8

Basic information

• Product Name: tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidine-1-carboxylate
• Synonyms: tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidine-1-carboxylate;Tert-butyl (S)-3-(4-(7-((aminooxy)carbonyl)-2H -indazol-2-yl)phenyl)piperidine-1-carboxylate
• CAS NO: 1038916-11-8
• Molecular Formula: C₂₄H₂₈N₄O₃
• Molecular Weight: 420.50412
• Mol File: 1038916-11-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidine-1-carboxylate(1038916-11-8)
• EPA Substance Registry System: tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidine-1-carboxylate(1038916-11-8)

Safety Data

• Hazardous Substances Data: 1038916-11-8(Hazardous Substances Data)

Usage

General Description

Tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidine-1-carboxylate is a chemical compound consisting of a piperidine ring attached to a benzene ring and an indazole ring. It has a tert-butyl group at the nitrogen of the piperidine ring and an aminocarbonyl group attached to the indazole ring. tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidine-1-carboxylate is a piperidine derivative with potential pharmaceutical applications due to its structural features, which could interact with biological receptors or enzymes. Its molecular structure suggests a potential role in modulating cellular processes and potentially serving as a drug candidate for various biological targets. Further research is needed to investigate the pharmacological properties and potential therapeutic applications of tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidine-1-carboxylate.

Upstream product

• 1038916-08-3 2-{4-[(3S)-1-(tert-butoxycarbonyl)piperidin-3-yl]phenyl}-2H-indazole-7-carboxylic acid 
• 1196713-67-3 2-[4-((3S)-(tertbutoxycarbonyl)piperidin-3-yl)phenyl]-2H-indazole-7-carboxylic acid methyl ester 
• 1171197-20-8 (3S)-3-(4-aminophenyl)piperidine-1-carboxylic acid tert-butyl ester 
• 132874-06-7 methyl 3-(bromomethyl)-2-nitrobenzoate 
• 586-78-7 para-nitrophenyl bromide 
• 1692-25-7 3-pyridylboronic acid 
• 68109-89-7 β-(dimethylamino)-3-carbomethoxy-2-nitrostyrene 
• 19733-56-3 3-(4-aminophenyl)piperidine 
• 5471-82-9 methyl 3-methyl-2-nitrobenzoate 
• 4282-46-6 3-(4'-nitrophenyl)pyridine 
• 1312106-32-3 18-(nitrobenzylideneamino)phenylpiperidine-1-carboxylate 
• 1196713-21-9 (3S)-3-(4-aminophenyl)piperidine 
• 138229-59-1 3-formyl-2-nitrobenzoic acid methyl ester 
• 875798-79-1 3-(4-aminophenyl)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1038915-73-9 2-[4-((3S)-3-piperidinyl)phenyl]-2H-indazole-7-carboxamide p-toluenesulfonic acid salt 
• 1171196-94-3 (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidinium fumarate 
• 1171196-88-5 (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidinium sulfate 
• 1038915-64-8 (3S)-3-[4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl]piperidinium chloride 

Relevant articles and documents

PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF

The present invention relates to novel procedures and novel intermediates useful in the synthesis of Niraparib or any salt thereof.

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors

We disclose the development of a novel series of 2-phenyl-2H-indazole-7- carboxamides as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells. Extrahepatic oxidation by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported. These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide 56 (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clinical trials. This compound displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. Compound 56 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.